This medication is applied across several therapeutic domains for short-term symptomatic support in situations involving pronounced inflammatory states. This medicine is commonly used to help with acute or episodic symptom management across several domains.

The therapeutic scope is relevant for managing symptoms related to inflammatory or irritative states in conditions characterized by periods of heightened symptoms. This includes exacerbations of Multiple Sclerosis, pronounced flare-ups of inflammatory bowel diseases (Crohn's Disease, Ulcerative Colitis), severe Juvenile Rheumatoid Arthritis, and refractory skin disorders like Pemphigus. It is relevant for managing symptoms that interfere with daily comfort, providing supportive relief that may help patients cope more steadily with symptom fluctuations.

Synacthen is applied in contexts where additional symptomatic support is needed in specific challenging conditions, often used during phases when symptoms intensify. The core benefit is providing supportive relief that assists with maintaining functional stability and contributes to improved day-to-day comfort during periods of heightened discomfort, relevant in contexts involving specific patient needs or preferences.

---

Quick Fact: Symptomatic Support

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, offering symptomatic support to help ease the overall symptom burden in situations where symptoms create noticeable physiological strain.

Regulatory References

1. Health Canada Product Monograph

Synacthen (tetracosactide) is generally available for diagnostic use in screening for adrenocortical insufficiency in adults and children. Its use is subject to specific regulatory restrictions to avoid serious adverse effects or compromised test accuracy.

Contraindicated Populations

Use of Synacthen is strictly contraindicated for several patient groups based on official regulatory labeling. These include individuals with known hypersensitivity or allergy to tetracosactide or ACTH, especially those with pre-existing asthma or other allergic disorders due to the high risk of anaphylaxis. It is also prohibited for patients with certain active conditions, such as acute psychosis, infectious diseases (unless managed with antibiotics), peptic ulcer, refractory congestive heart failure, and specific pre-existing endocrine conditions like Cushing's syndrome, primary adrenocortical insufficiency, and adrenogenital syndrome.

Use Restrictions and Special Considerations

• Pregnancy and Lactation: Synacthen is generally contraindicated during pregnancy and breastfeeding.
• Age: Special caution or formulation differences apply to neonates and premature babies due to excipients in some product types. Pediatric doses for the diagnostic test are often adjusted by age.
• Condition-Specific Caution: Caution and dosage adjustments for concomitant medicines are necessary for patients with diabetes mellitus or moderate to severe hypertension. Caution is also advised for those with conditions like renal impairment, hepatic impairment, non-specific ulcerative colitis, or a predisposition to thromboembolism.

Interactions with other medicines and products

The interaction profile for Tetracosactide is defined by the systemic effects of the endogenous corticosteroids released after the adrenal cortex is stimulated. These are classified in regulatory documents as pharmacodynamic interactions that result in either additive risks or functional antagonism.

Interaction Scope	Official Regulatory Information
Medicinal product categories with documented interactions	Diuretics (Potassium-Depleting), Cardiac Glycosides, Antidiabetic Agents, Oral Anticoagulants, NSAIDs, Antihypertensive Agents.
Mechanistic basis of interactions	Pharmacodynamic Interaction (Additive and Antagonistic effects) resulting from high endogenous corticosteroid levels.
Interaction-related restrictions	Co-administration with Live Vaccines is formally contraindicated. Co-administration with Liquorice (licorice) preparations is noted to increase the action and toxicity of the induced corticosteroid effect.

Official Interaction Statements

• Co-administration with Live Vaccines is formally contraindicated in official labeling.
• Combining with potassium-depleting diuretics increases the regulatory-documented risk of hypokalemia.
• The use of Tetracosactide may reduce the effectiveness of antidiabetic agents and antihypertensive agents.
• Co-administration with Cardiac Glycosides increases the risk of digitalis toxicity if hypokalemia occurs.
• Concurrent use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) increases the official regulatory risk of gastrointestinal bleeding and ulceration.

These statements define a structure based on severity, including one contraindicated combination and several interactions related to increased physiological risk or drug efficacy antagonism as documented by health authorities.

Synacthen (tetracosactide) functions as a synthetic polypeptide ACTH (1-24) analogue, exhibiting agonist activity at the adrenocorticotropic hormone (ACTH) receptor, primarily located on the plasma membrane of adrenocortical cells in the zona fasciculata and reticularis of the adrenal cortex.

Binding of Synacthen to the receptor initiates an intracellular signaling cascade involving the G-protein-coupled receptor activation of adenylate cyclase. This enzymatic reaction leads to a rapid increase in the production of cyclic adenosine monophosphate (cAMP), the primary second messenger. Elevated cAMP levels subsequently activate Protein Kinase A (PKA).

Activated PKA drives the phosphorylation of regulatory proteins, promoting the transport of cholesterol into the mitochondria, the rate-limiting step in steroidogenesis. The ultimate downstream cascade is the enzymatic synthesis and secretion of adrenal steroids, chiefly glucocorticoids (e.g., cortisol) and, to a lesser extent, mineralocorticoids and androgens. This system-level physiological consequence modulates circulating concentrations of these hormones.

Administration Overview

Synacthen is administered by healthcare professionals in a clinical setting. The method of administration depends on the specific formulation being used and the purpose of the clinical assessment. It is typically given as an injection, either into a muscle or into a vein.

Clinical Environment

Because the use of this medication often involves monitoring physiological responses, it is administered under the supervision of medical staff. The procedure is usually performed in a hospital or specialized outpatient clinic where necessary equipment is available to record observations and manage the process.

Preparation for Use

Before the procedure begins, healthcare providers ensure that the solution is clear and free of particles. Depending on the specific diagnostic test being performed, patients may be asked to remain in a resting position during and after the administration to ensure accurate results.

Monitoring During Administration

Medical personnel remain present during the process to monitor the patient's status. This includes observing for any immediate reactions and ensuring that the substance is delivered at the appropriate rate as determined by the clinical protocol. After the injection, patients are typically kept under observation for a specific period of time.

Research evidence / Overview of studies for Synacthen

---

Evidence for the Diagnostic Use: Testing Adrenal Function

Synacthen (Tetracosactide) was studied for its use as the Short Synacthen Test (SST), a standard diagnostic procedure. Research examined its use for assessing the functional capacity of the Hypothalamic-Pituitary-Adrenal (HPA) axis. Studies exploring this function included diagnostic accuracy studies, where SST results were compared against other established tests. Researchers conducted retrospective observational studies and cross-sectional analyses to establish appropriate levels of response. Studies focused on exploring the test’s accuracy in identifying patients with adrenal insufficiency by monitoring the peak serum cortisol response at short time intervals. The research examined the test's sensitivity and specificity; however, the precise cortisol thresholds may vary across studies because different laboratory assay methods were observed to produce slightly different measurements, meaning results apply only to the populations studied under those specific conditions.

---

Evidence for Therapeutic Use: Symptomatic Support in Acute Conditions

For therapeutic use with the Depot formulation, research was evaluated in the context of providing short-term symptomatic support during acute episodes of specific diseases, known as conditions characterized by fluctuating or episodic manifestations. The evidence primarily comes from historical Randomized Controlled Trials (RCTs), supplemented by supporting observational studies. Research explored outcomes related to physical discomfort and episodic or acute changes in conditions such as Multiple Sclerosis exacerbations and pronounced flare-ups of Inflammatory Bowel Diseases. These studies examined metrics related to functional stability and inflammatory or irritative outcomes during periods of increased symptom activity. Findings reported measurements of changes in symptom levels and functional markers during the acute treatment phase. However, the therapeutic evidence is derived from trials that were conducted using methodologies that may differ from current standards and typically involve smaller cohorts.

---

Long-Term Data, Special Populations, and Research Uncertainty

Research was studied for long-term outcomes, including long-term observational follow-up to assess the predictive accuracy of the diagnostic test. For therapeutic use, follow-up durations were limited to the short-to-medium term, meaning long-term effects are not fully established concerning chronic disease control.

Research has examined the diagnostic test in pediatric populations (children) and patients with pituitary disease. The overall data for certain groups remain insufficient.

Regulatory reviews indicate several areas where certainty remains low. The interpretation of the diagnostic SST test may be uncertain due to variability in cortisol assay methods. For the therapeutic Depot formulation, comparative evidence is lacking from recent, large-scale RCTs comparing its use to contemporary treatments.

Key Studies & References

1. Health Canada Product Monograph (Synacthen Depot) - Therapeutic Indications and Study Structure
2. Tetracosactide Drug Information - MedlinePlus (NIH)

Common questions about Synacthen (FAQ)

---

Q: How quickly does Synacthen start to work after getting the injection?

When Synacthen is used for diagnostic testing, the stimulation of the adrenal glands happens very rapidly. Official product information for the test procedure often involves taking the first blood sample just 30 minutes after the injection to measure the initial hormonal response.

Q: How is Synacthen different from cortisol medication?

Synacthen is a synthetic hormone that is designed to stimulate your own adrenal glands to produce and release natural cortisol. In contrast, cortisol medications are taken externally to directly supply the hormone to the body. These two types of medicines are described as influencing hormone levels through distinct mechanisms.

Q: Does Synacthen help with long-term conditions?

The official therapeutic uses for the long-acting Depot form are defined for short-term symptomatic support during acute episodes or flare-ups of certain conditions. Regulatory reviews indicate that long-term effects relating to chronic disease control are not fully established in research.

Q: Can Synacthen be used during pregnancy?

Official regulatory information advises that the medicine should generally be avoided during pregnancy. Regulatory documents state that it is reserved for situations where the treating physician determines the benefit to the patient outweighs potential risks to the fetus.

Q: Can people with diabetes use Synacthen?

People with diabetes may use Synacthen, but official documents highlight that close monitoring is typically required, as Synacthen may cause a temporary rise in blood sugar levels. It may also reduce the effectiveness of medicines used to control diabetes.

Q: Does Synacthen affect the immune system?

Synacthen stimulates the adrenal glands to release natural steroid hormones, primarily cortisol, which are known to have wide-ranging effects on the body, including the immune response. Official labeling states that co-administration with live vaccines is formally contraindicated.

Q: Is it true that Synacthen can cause weight gain?

Fluid and salt retention, known as oedema (swelling), is listed as an uncommon side effect in official documents. Furthermore, prolonged therapeutic use is associated with a risk of developing Cushingoid features, which may include weight-related changes.

Q: Will I feel tired or dizzy after the injection?

Dizziness is listed in official product information as a possible side effect, particularly in the context of a hypersensitivity reaction. Fatigue or tiredness is not typically listed as a common or uncommon side effect.

Q: Can Synacthen be used in children?

Yes, Synacthen is approved for use in children, and the therapeutic dose is adjusted based on the child's age and clinical response. Official product information notes an increased risk of gastrointestinal hemorrhage in children with severe gastrointestinal inflammatory conditions.

Q: How long does the effect of a Synacthen injection last?

The solution form, used for diagnostic testing, is noted as being short-acting. The Depot (suspension) form, used for therapeutic purposes, is designed to release the active ingredient slowly, providing a sustained hormonal effect over a longer period.

Q: What happens if a dose of Synacthen is missed?

Official consumer information advises that a healthcare provider should be contacted immediately if a scheduled therapeutic dose is missed. It also notes against taking an extra dose to compensate for the missed one.

Q: Is Synacthen an anti-inflammatory drug?

Synacthen is a hormone analogue that stimulates the adrenal glands. It is not directly classified as an anti-inflammatory drug, but it causes the release of cortisol, which is a natural steroid hormone known for its anti-inflammatory properties.

Q: What are the possible skin reactions at the injection site?

Redness or pain at the injection site is listed as a possible sign of a local allergic or hypersensitivity reaction. General skin changes, such as acne, are also listed as common side effects of the medication.

Q: Is it safe to drive after receiving a Synacthen injection?

Official regulatory warnings note that this medicine may cause side effects like headache or vertigo (a spinning sensation). Official warnings suggest that patients should determine if they experience these effects before driving or operating machinery.

Q: Why do I need blood tests when using Synacthen?

Blood tests are necessary for two main reasons. They are required for the diagnostic test to measure the body's cortisol response. For therapeutic use, blood tests may be required to monitor for side effects like changes in blood pressure, blood sugar, and potassium levels.

Q: What does Synacthen do to the adrenal glands?

Synacthen is a synthetic hormone designed to stimulate the adrenal glands directly. This action causes the glands to rapidly increase their internal production and release of the body's natural steroid hormones, primarily cortisol.

Q: Can Synacthen affect my mood or cause anxiety?

Official documents list mood alterations, including rapid changes in mood, and difficulty sleeping (insomnia) as known side effects. Official documentation advises that any significant mood alteration be discussed with a healthcare provider.

Q: Is there a generic version of Synacthen available?

Synacthen contains the active ingredient tetracosactide, which is also known as cosyntropin. While cosyntropin is available in a generic form in some regions for diagnostic use, the specific long-acting Depot formulation of Synacthen is not approved in all markets, such as the United States.

Q: Is there a maximum time someone can use Synacthen?

The official product information defines therapeutic use as a 'short-term therapy' for acute conditions. Warnings indicate that the risk of certain serious effects, such as osteoporosis and Cushingoid features, is associated with prolonged or long-term therapeutic use.

Q: What official information is available about Synacthen in the US?

In the United States, the Food and Drug Administration (FDA) has approved the active ingredient, tetracosactide (cosyntropin), for diagnostic testing of adrenal function. The long-acting Depot formulation of Synacthen is not currently approved for use in the US.

Q: How soon after stopping Synacthen do its effects wear off?

The effects of therapeutic treatment will gradually wear off after the drug is stopped. For therapeutic use, regulatory guidance specifies that discontinuing treatment typically requires a healthcare professional to gradually reduce or 'taper' the dosage.

Q: Can Synacthen be used for conditions not specifically listed in its main uses?

Official regulatory documents define the specific conditions (indications) for which the drug is approved. Regulatory bodies restrict pharmaceutical companies from promoting a drug for any conditions that are not explicitly listed in the official approved uses.

Q: Is there a specific time of day Synacthen is usually given?

The diagnostic Synacthen test is commonly performed in the morning, often around 9:00 AM. This timing is standard because it aligns with the body's natural circadian rhythm of cortisol production, providing a more reliable baseline for testing adrenal function.

Q: Is Synacthen only used in hospitals or clinics?

The medication is administered by injection, either intravenously (into a vein) or intramuscularly (into a muscle). Due to its administration by injection, regulatory documents describe that Synacthen is typically administered under the supervision of a medical professional.

Q: Can using Synacthen cause temporary hair loss?

The official documentation for the Depot form lists an 'unusual increase in hair growth on body or face' as a potential side effect. Hair loss itself is not listed as a known adverse reaction.

Q: Why is Synacthen not a first-line treatment for many conditions?

The official therapeutic indications for the Depot formulation generally specify its use as a 'short-term' option for acute exacerbations of certain conditions. This context suggests it is typically reserved for specific, defined clinical situations rather than being a primary, first-choice agent.

Q: How does Synacthen relate to the body's stress response?

Synacthen works by stimulating the release of cortisol, which is the body's main stress hormone. The body naturally produces and releases cortisol to help regulate functions like metabolism and immune response during times of stress.

Q: What is the main research focus regarding Synacthen currently?

Current research involving the active ingredient, tetracosactide, includes exploring non-invasive methods of administration, such as nasal sprays for diagnostic testing. Studies also continue to investigate its potential therapeutic use in different medical conditions, such as certain kidney diseases.

Q: Can Synacthen cause a headache?

Yes, headache is listed in official documentation as a common side effect of the medication.

How to Store and Dispose of Synacthen

Synacthen (Tetracosactide) requires strict adherence to documented regulatory storage conditions to ensure the stability of the active ingredient.

Storage Conditions

Requirement	Specific Condition
Temperature	Store refrigerated between 2°C and 8°C (36°F and 46°F).
Protection	Keep in the original package to protect from light.
Safety	Keep out of the sight and reach of children (child-safety requirement).

---

Disposal

Any unused or expired Synacthen product, or associated waste material, must be disposed of in accordance with local requirements for pharmaceutical waste, as directed by official labeling.